207940.KS Samsung Biologics Co.,Ltd.
KSCHealthcareAs of 2026-08-09 03:18
Why 207940.KS matters now
Samsung Biologics Co.,Ltd. (207940.KS) is a Korea stock in Healthcare. The latest InvestLog snapshot shows ₩1,556,000.00 with +2.77% on the session and ₩72.03T in market capitalization.
Valuation context is available even where detailed statement rows are sparse: InvestLog currently shows P/E 36.28, gross margin 39.7%, and operating margin 43.7%.
The latest indexable market news headline is "Samsung Biologics Reports Second Quarter 2026 Financial Results" from PRNewsWire.
Valuation
P/E (TTM)
36.28
PEG
—
P/B
9.09
P/S
15.84
EV/EBITDA
25.58
DCF Value
—
FCF Yield
2.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
39.7%
Operating Margin
43.7%
Net Margin
43.6%
ROE
20.3%
ROA
16.5%
ROIC
15.4%
Latest News
Listing Info
Market
Korea
Exchange
KSC
Currency
KRW
Sector
Healthcare
Industry
Biotechnology
Country
KR
Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Organization (CMO) and Contract Development Organization (CDO). Its CDO services cover areas such as cell line development, optimization of upstream and downstream processes, and the formulation of analytical methods and final products. For CMO, the company offers aseptic filling, lyophilization, finishing, storage, shipping, and various associated support services. Additionally, it delivers comprehensive quality assurance, quality control, biosafety, and analytical testing. Samsung Biologics is also involved in creating and launching biosimilar drugs, alongside manufacturing mammalian cell-based antibody medications.